Voloridge Investment Management, LLC Fibrogen Inc Transaction History

Voloridge Investment Management, LLC

$26.2 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $596,327 - $4.93 Million	-239,489 Reduced 73.95%	84,370 $227,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $5.17 Million - $8.15 Million	323,859 New	323,859 $6.04 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $2.43 Million - $3.11 Million	-213,217 Reduced 57.07%	160,401 $2.09 Million
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $67,100 - $109,524	8,451 Added 2.31%	373,618 $3.95 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $227,947 - $318,405	-18,964 Reduced 4.94%	365,167 $4.39 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $4.35 Million - $6.74 Million	-438,200 Reduced 53.29%	384,131 $5.42 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $5.8 Million - $15.2 Million	569,939 Added 225.82%	822,331 $8.4 Million
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $4.69 Million - $9.01 Million	252,392 New	252,392 $6.72 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $1.25 Million - $1.4 Million	-30,819 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $1 Million - $1.32 Million	30,819 New	30,819 $1.25 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $323,753 - $638,614	-13,895 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $480,489 - $667,793	13,895 New	13,895 $596,000
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $660,250 - $897,562	-14,559 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $2.22 Million - $3.17 Million	-52,825 Reduced 78.39%	14,559 $690,000
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $2.25 Million - $3.63 Million	67,384	67,384 $3.63 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.

Account